A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Mpdl3280a (Anti−Pd-L1 Antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Pd-L1−Selected Patients with Completely Resected Stage Ib−IIIa Non−Small Cell Lung Cancer

UCI-15-47
NCT02486718
Cancer - Lung
Sai-Hong Ignatius Ou
Open
Treatment
Atezolizumab, MPDL3280A
III
Adult
Local

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.